Servicios Personalizados
Revista
Articulo
Español (pdf)
Articulo en XML
Referencias del artículo
Traducción automática
Enviar articulo por emailIndicadores
Citado por SciELO 
Accesos
Links relacionados
Citado por Google 
Similares en
SciELO 
Similares en Google
Compartir
Permalink
Revista Colombiana de Reumatología
versión impresa ISSN 0121-8123
Resumen
MORA, Claudia et al. Prevalence of latent tuberculosis determined using the Purified Protein Derivative (PPD) test in adult patients with rheumatoid arthritis receiving biotechnological therapy. Rev.Colomb.Reumatol. [online]. 2021, vol.28, n.3, pp.178-183. Epub 16-Ene-2022. ISSN 0121-8123. https://doi.org/10.1016/j.rcreu.2020.08.004.
Introduction:
Although tuberculosis (TB) is endemic in Columbia, with a prevalence of 26 cases per million, there are no recent and clear data regarding the prevalence of latent tuberculosis (LBT) in the population with rheumatoid arthritis (RA), candidates for biotechnological therapy.
Methodology:
A cross-sectional study with an analytical component to determine the prevalence of LBT in patients with RA who are candidates for biotechnological therapy.
Results:
The prevalence of LTB in RA patients who are candidates for biotechnological therapy is high, 18.3% (95% CI: 14.7-21.9). In the exploratory analysis, a relationship between LBT and male gender was found (P ≤ .001), as well as abnormal findings on chest radiography (P = .039), and smoking (P = .028).
Conclusion:
The prevalence of LTB in patients with RA who are candidates for biotechnological therapy is high. Prospective studies are needed to evaluate the incidence of TB in this group of patients and corroborate this association.
Palabras clave : Latent tuberculosis; Tuberculosis; Rheumatoid arthritis; Biotechnological therapy; Anti-TNF; Rheumatic diseases; Prevalence.
